Physician profile
Timothy R Gilbert
NPI 1467568600
$984,503.14
in general payments reported to CMS, 2019-2025
60 companies · $71K in 2025
The $71K reported for 2025 was more than what 97% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251K · 2020: $145K · 2021: $203K · 2022: $139K · 2023: $82K · 2024: $93K · 2025: $71K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $130K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $75K · Travel and Lodging: $26K · Food and Beverage: $11K · Consulting Fee: $4,117 · Education: $12.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $130,166.29 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $75,260.00 |
| Travel and Lodging | $25,698.45 |
| Food and Beverage | $11,367.24 |
| Consulting Fee | $4,117.00 |
| Education | $12.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $339,295.34 | 2019-2023 | Farxiga, Lokelma |
| Novo Nordisk INC | $269,721.89 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Dexcom, INC. | $242,238.69 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $87,786.53 | 2019-2025 | |
| Insulet Corporation | $13,009.51 | 2019-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12,792.60 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $8,576.16 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Senseonics, Incorporated | $3,500.00 | 2019 | |
| Medtronic, INC. | $1,845.52 | 2021-2025 | Minimed 780g |
| Abbott Laboratories | $554.69 | 2019-2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $368.44 | 2020-2023 | Nexletol |
| Abbvie INC. | $339.80 | 2019-2024 | |
| Kvk-Tech, INC. | $326.38 | 2019 | |
| Horizon Therapeutics Plc | $295.17 | 2021-2023 | Tepezza |
| Merck Sharp & Dohme LLC | $295.05 | 2019-2022 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $272.50 | 2020-2023 | Signifor Lar, Isturisa |
| Xeris Pharmaceuticals, INC. | $260.07 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Corcept Therapeutics | $255.70 | 2019-2024 | Korlym |
| Antares Pharma, INC. | $244.32 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Amgen INC. | $205.86 | 2020-2025 | Tepezza, Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $147.92 | 2022-2025 | |
| Averitas Pharma INC. | $136.68 | 2023-2024 | Qutenza |
| Grt US Holding, INC. | $134.65 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $126.43 | 2019-2022 | |
| Amarin Pharma, INC. | $126.10 | 2019-2021 | |
| Genentech, INC. | $120.19 | 2025 | |
| Eusa Pharma (US) LLC | $114.25 | 2022 | |
| Amryt Pharma Holdings Ltd | $107.30 | 2020-2023 | Mycapssa, Myalept |
| Ultragenyx Pharmaceutical INC. | $106.86 | 2019-2022 | |
| Astellas Pharma US INC | $90.95 | 2023-2024 | Veozah |
| Shire North American Group INC | $88.70 | 2019 | |
| Tolmar, INC. | $81.73 | 2023-2024 | |
| Tandem Diabetes Care, INC. | $80.16 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Alexion Pharmaceuticals, INC. | $71.03 | 2019-2023 | Strensiq |
| Mannkind Corporation | $59.40 | 2022 | |
| Madrigal Pharmaceuticals | $57.84 | 2025 | Rezdiffra |
| Janssen Pharmaceuticals, INC | $56.77 | 2019 | |
| Endo Pharmaceuticals INC. | $55.09 | 2019-2021 | |
| Medtronic Minimed, INC. | $47.47 | 2019-2020 | |
| Rhythm Pharmaceuticals, INC. | $47.29 | 2023-2025 | Imcivree, Imcivree |
| Vivus LLC | $45.89 | 2019-2020 | |
| Ibsa Pharma INC. | $38.68 | 2020 | |
| Kyowa Kirin, INC. | $37.15 | 2023-2024 | Crysvita |
| Acella Pharmaceuticals, LLC | $35.12 | 2025 | NP Thyroid 60 |
| Novartis Pharmaceuticals Corporation | $28.21 | 2022 | |
| Halozyme INC | $26.66 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $25.25 | 2023 | Somatuline Depot |
| Aytu Biopharma, INC. | $21.85 | 2019 | |
| Beta Bionics, INC. | $21.12 | 2024 | Ilet Bionic Pancreas |
| Ascendis Pharma Endocrinology INC | $20.84 | 2024 | |
| Companion Medical, INC. | $20.35 | 2019 | |
| Nevro Corp. | $19.81 | 2022 | |
| Currax Pharmaceuticals LLC | $17.07 | 2025 | Contrave |
| Aegerion Pharmaceuticals, INC. | $16.33 | 2019 | |
| Clarus Therapeutics INC. | $15.56 | 2021 | |
| Radius Health, INC. | $15.50 | 2019 | |
| Pfizer INC. | $15.34 | 2021 | |
| Acerus Pharmaceuticals Corporation | $14.17 | 2022 | |
| Cequr Corporation | $13.99 | 2024 | Cequr Simplicity |
| Takeda Pharmaceuticals U.S.A., INC. | $13.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.